A pilot study of MRI radiomics for high‐risk prostate cancer stratification in 1.5 T MR‐guided radiotherapy

To investigate the potential value of MRI radiomics obtained from a 1.5 T MRI‐guided linear accelerator (MR‐LINAC) for D'Amico high‐risk prostate cancer (PC) classification in MR‐guided radiotherapy (MRgRT).

[1]  Jing Yuan,et al.  1.5T Magnetic Resonance-Guided Stereotactic Body Radiotherapy for Localized Prostate Cancer: Preliminary Clinical Results of Clinician- and Patient-Reported Outcomes , 2021, Cancers.

[2]  K. Izumi,et al.  Treatment Strategies for High-Risk Localized and Locally Advanced and Oligometastatic Prostate Cancer , 2021, Cancers.

[3]  B. Erickson,et al.  Patterns of care, tolerability and safety of the first cohort of patients treated on a novel high-field MR-Linac within the MOMENTUM Study: Initial results from a prospective Multi-Institutional Registry. , 2021, International journal of radiation oncology, biology, physics.

[4]  Alisa S. Bettermann,et al.  Radiomics in prostate cancer imaging for a personalized treatment approach - current aspects of methodology and a systematic review on validated studies , 2021, Theranostics.

[5]  Oi Lei Wong,et al.  Radiomics feature reliability assessed by intraclass correlation coefficient: a systematic review. , 2021, Quantitative imaging in medicine and surgery.

[6]  F. Alongi,et al.  MR-Guided Hypofractionated Radiotherapy: Current Emerging Data and Promising Perspectives for Localized Prostate Cancer , 2021, Cancers.

[7]  Binsheng Zhao.  Understanding Sources of Variation to Improve the Reproducibility of Radiomics , 2021, Frontiers in Oncology.

[8]  Saima Rathore,et al.  Magnetic Resonance Imaging Based Radiomic Models of Prostate Cancer: A Narrative Review , 2021, Cancers.

[9]  L. Beckman,et al.  Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer (HYPO-RT-PC): patient-reported quality-of-life outcomes of a randomised, controlled, non-inferiority, phase 3 trial. , 2021, The Lancet. Oncology.

[10]  R. Verma,et al.  The Pursuit of Generalizability to Enable Clinical Translation of Radiomics. , 2021, Radiology. Artificial intelligence.

[11]  H. G. van der Poel,et al.  EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer-2020 Update. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. , 2020, European urology.

[12]  M. Leech,et al.  Mini review: Personalization of the radiation therapy management of prostate cancer using MRI-based radiomics. , 2020, Cancer letters.

[13]  A. Richetti,et al.  Cone-beam computed tomography-based radiomics in prostate cancer: a mono-institutional study , 2020, Strahlentherapie und Onkologie.

[14]  P. Summers,et al.  MRI-based radiomics signature for localized prostate cancer: a new clinical tool for cancer aggressiveness prediction? Sub-study of prospective phase II trial on ultra-hypofractionated radiotherapy (AIRC IG-13218) , 2020, European Radiology.

[15]  R. Stoyanova,et al.  The role of radiomics in prostate cancer radiotherapy , 2020, Strahlentherapie und Onkologie.

[16]  M. Dietzel,et al.  A decade of radiomics research: are images really data or just patterns in the noise? , 2020, European Radiology.

[17]  A. Madabhushi,et al.  Combination of Peri-Tumoral and Intra-Tumoral Radiomic Features on Bi-Parametric MRI Accurately Stratifies Prostate Cancer Risk: A Multi-Site Study , 2020, Cancers.

[18]  V. Kataja,et al.  Stereotactic body radiotherapy for localized prostate cancer – 5-year efficacy results , 2020, Radiation oncology.

[19]  S. Senan,et al.  Magnetic Resonance-guided Stereotactic Radiotherapy for Localized Prostate Cancer: Final Results on Patient-reported Outcomes of a Prospective Phase 2 Study. , 2020, European urology oncology.

[20]  R. Cuocolo,et al.  Prostate MRI radiomics: A systematic review and radiomic quality score assessment. , 2020, European journal of radiology.

[21]  G. Rodrigues,et al.  Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial , 2019, The Lancet. Oncology.

[22]  S. Roy,et al.  Who Dies From Prostate Cancer? An Analysis of the Surveillance, Epidemiology and End Results Database. , 2019, Clinical oncology (Royal College of Radiologists (Great Britain)).

[23]  L. Beckman,et al.  Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial , 2019, The Lancet.

[24]  F. Alongi,et al.  Moderate versus extreme hypofractionated radiotherapy: a toxicity comparative analysis in low- and favorable intermediate-risk prostate cancer patients , 2019, Journal of Cancer Research and Clinical Oncology.

[25]  P. Lambin,et al.  CT-based Radiomics for Risk Stratification in Prostate Cancer. , 2019, International journal of radiation oncology, biology, physics.

[26]  A. D'Amico,et al.  Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. , 2019, Journal of the National Comprehensive Cancer Network : JNCCN.

[27]  Prashanth Rawla,et al.  Epidemiology of Prostate Cancer , 2019, World journal of oncology.

[28]  Stefan Leger,et al.  Image biomarker standardisation initiative version 1 . 4 , 2016, 1612.07003.

[29]  F. Montorsi,et al.  Stratification of high-risk prostate cancer into prognostic categories: a European multi-institutional study. , 2015, European urology.

[30]  Jan J W Lagendijk,et al.  MR guidance in radiotherapy , 2014, Physics in medicine and biology.

[31]  Sasa Mutic,et al.  The ViewRay system: magnetic resonance-guided and controlled radiotherapy. , 2014, Seminars in radiation oncology.

[32]  Jan-Jakob Sonke,et al.  Magnetic resonance-guided adaptive radiotherapy: a solution to the future. , 2014, Seminars in radiation oncology.

[33]  Jan J W Lagendijk,et al.  The magnetic resonance imaging-linac system. , 2014, Seminars in radiation oncology.

[34]  P. Lambin,et al.  Decoding tumour phenotype by noninvasive imaging using a quantitative radiomics approach , 2014, Nature Communications.

[35]  Howard I. Scher,et al.  High-risk prostate cancer—classification and therapy , 2014, Nature Reviews Clinical Oncology.

[36]  J. Lebesque,et al.  Long-term results of the Dutch randomized prostate cancer trial: impact of dose-escalation on local, biochemical, clinical failure, and survival. , 2014, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[37]  M. Parmar,et al.  Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial , 2011, The Lancet.

[38]  C. L. Cutajar,et al.  External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study. , 2010, The Lancet. Oncology.

[39]  M. Cooperberg,et al.  High-risk prostate cancer in the United States, 1990–2007 , 2008, World Journal of Urology.

[40]  M. Parmar,et al.  Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial. , 2007, The Lancet. Oncology.

[41]  Daniel W. Miller,et al.  Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial. , 2005, JAMA.

[42]  A. Renshaw,et al.  Biochemical Outcome after radical prostatectomy, external beam Radiation Therapy, or interstitial Radiation therapy for clinically localized prostate cancer , 1998 .